Allarity Therapeutics (ALLR) closed at $0.98 on November 2, 2026, up 12.4% from the previous close, on volume of 160,739 shares (30-day average 125,571).
Data as of November 2, 2026.
Allarity Announces First Revenue-Generating Laboratory Services Contract
TipRanks (Mon, 2-Nov 8:40 AM ET)
Allarity Therapeutics Ends Stock Purchase Agreement, Shifts Financing
TipRanks (Fri, 30-Oct 5:05 PM ET)
Globe Newswire (Fri, 30-Oct 7:45 AM ET)
Globe Newswire (Wed, 30-Sep 9:00 AM ET)
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
Globe Newswire (Tue, 15-Sep 8:00 AM ET)
Globe Newswire (Fri, 11-Sep 8:00 AM ET)
Globe Newswire (Fri, 14-Aug 8:00 AM ET)
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Allarity Therapeutics trades on the NASDAQ stock market under the symbol ALLR.
As of November 2, 2026, ALLR stock price climbed to $0.98 with 160,739 million shares trading.
ALLR has a beta of 1.97, meaning it tends to be more sensitive to market movements. ALLR has a correlation of 0.09 to the broad based SPY ETF.
ALLR has a market cap of $15.56 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ALLR traded as high as $666.00 and as low as $.61.
The top ETF exchange traded funds that ALLR belongs to (by Net Assets): VXF.
ALLR has underperformed the market in the last year with a return of -30.2%, while the SPY ETF gained +11.7%. In the last 3 month period, ALLR fell short of the market, returning -20.5%, while SPY returned +1.7%. However, in the most recent 2 weeks ALLR has outperformed the stock market by returning +9.2%, while SPY returned -1.5%.
ALLR support price is $.82 and resistance is $.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLR shares will trade within this expected range on the day.
